Synthetic organic

BLZ945 is a tumor-associated macrophage targeting the treatment of glioblastoma multiforme, a most common type of aggresive brain cancer.

BLZ945 is a tumor-associated macrophage targeting the treatment of glioblastoma multiforme, a most common type of aggresive brain cancer.

BLZ945 is a tumor-associated macrophage targeting the treatment of glioblastoma multiforme, a most common type of aggresive brain cancer.

BML-278 is a selective Sirt1 activator (EC|150|= 1μM) structurally based on a dihydropyridine scaffold. It has much weaker effects on Sirt2 and Sirt3. BML-278 is active in whole cells and arrests cell cycle at G1/S phase in U937 cells.

BML-278 is a selective Sirt1 activator (EC|150|= 1μM) structurally based on a dihydropyridine scaffold. It has much weaker effects on Sirt2 and Sirt3. BML-278 is active in whole cells and arrests cell cycle at G1/S phase in U937 cells.

BMS 181,101.

BMS 181,101.

Pan-RAR inverse agonist.

Pan-RAR inverse agonist.

Potent, selective RARα agonist.

Potent, selective RARα agonist.

Potent, selective RARα agonist.